Short answer
Intellia Therapeutics, Inc. (NTLA) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $8M (down 46.2% year over year) with net income of −$107M.
Q2 2026 key financials · XBRL
- Revenue
- $8M
- −46.2% YoY · −49.1% QoQ
- Net income
- −$107M
- −5.3% YoY · −10.8% QoQ
- Operating margin
- -1472.3%
- EPS (diluted)
- −$0.80
- +18.4% YoY · +1.2% QoQ
Source: XBRL data from the Intellia Therapeutics, Inc. (NTLA) Q2 2026 10-Q on SEC EDGAR. USD.
Intellia Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $7.659M, down $6.586M YoY from $14.245M
- Operating loss $112.760M vs $109.996M; net loss $106.634M vs $101.255M
- Nex-z largest R&D program at $18.268M; lonvo-z $9.569M
- Lonvo-z HAELO attacks reduced 87% versus placebo; mean monthly rate 0.26 vs 2.10
- Lonvo-z BLA submission expected second half 2026; U.S. launch planned first half 2027 if approved
Risk Factors
- Newly added CRISPR validation risk: in-vivo genome-editing therapies remain largely unproven, with no such therapy approved in the U.S. or EU
- Most material update: FDA lifted MAGNITUDE and MAGNITUDE-2 clinical holds in Q1 2026 after Grade 4 liver injury and bilirubin elevations
- Regulatory risk: FDA may require additional toxicology, biodistribution, reproductive-health studies, or 15-year patient follow-up
- Near-term operational risk: MAGNITUDE and MAGNITUDE-2 resumption may face further regulatory or patient-safety delays
- Financial risk: continued net losses and no product-sales revenue create dependence on successful future commercialization
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Intellia Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.